TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Quality of Parent-child Relationship
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent of Eligible Participants Who Enroll
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ocular Surface Disease Index (OSDI) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Schirmer I Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conjunctival Goblet Cell Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Four-month Progression-free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Any Subjects Experiencing Any Safety Related Events
Endpoint domain: Adverse events/effects
Primary endpoint: area under the plasma concentration-time curve during a dosing interval (AUCτ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: observed maximum plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Quality of Life Related to Health (HRQoL) at 6 month
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from number of hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Ventricular response to exercise training
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to First Event: Pulse Oximetry at 95%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to First Event: Successful Intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Analysis of perspired protein fragments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of All Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of GERD Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Average Number of Weekly Post-Prandial Blood Glucose Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Social Skills Improvement System Rating Scales - Parent
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Social Skills Improvement System Rating Scales - Child
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Area under the curve (AUC) of FORE8394
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration (Cmax) of FORE8394
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to peak concentration (Tmax) of FORE8394
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knowledge level of pregnant women on nutrition
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: appropriate nutrition-related practice
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fractional perfusion (f)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue diffusion (Dt)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transfer constant (Ktrans)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of de novo lipogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Calories Used
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of In-Treatment Pregnancies Per 100 Woman Years of Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percent Change BOLD Signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change in visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percentage of 24hrs pH>4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: elevated NT-proBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Inhibition of ADP-receptors on thrombocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Edinberg Postnatal Depression Scale (EPDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: changes in inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug-related AEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment Discontinuation for AEs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients leaving PEP treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pulsatility Indices (PI) of Spiral Artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Resistive Indices (PI) of Spiral Artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Uterine Artery Resistive Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Uterine Artery Pulsatility Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: % successful scans in three tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance with professional testers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lay user's ability to repeat a urine test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and Severity of Observed or Self-reported Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Malaria Clinical Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First PCR Positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory reinnervation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Motor reinnervation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quick Disabilities of the Arm, Shoulder and Hand score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: number of oocytes retrieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: number of embryos generated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Changes in cardiovascular variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in HRV frequency domain variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of opioids drug administered
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Complete Spontaneous Bowel Motions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Evidence of clinical dehydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number Usable PET/MRI Image Sets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Diagnostic Quality Images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale (VAS) for back and legs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Simultaneous seroprotection percentages for neutralizing poliovirus antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Achievement of successful ovulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum creatinine and blood urea nitrogen (BUN) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rates of Dyspareunia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of participants who could wear the device more than 90% of the time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily data acquisition rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posterior spinal fusion rate after one year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of (serious) adverse events with a potential relation with AttraX® Putty
Endpoint domain: Adverse events/effects
Primary endpoint: Massive Nasal Bleeding Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of successful cases in arresting bleeding
Endpoint domain: Physiological/clinical
Primary endpoint: time taken to arrest the bleeding
Endpoint domain: Physiological/clinical
Primary endpoint: Sense of Coherence (SoC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rosenberg Self Esteem Scale (RSES)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavior rated on the Child Behavior Checklist
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Need for Endotracheal Intubation
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Participant Self-rated health score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Self-efficacy in ability to continue essential life activities score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Independent self care agency score
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Box and Blocks Test (BBT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distant-disease free survival
Endpoint domain: Mortality/survival
Primary endpoint: Actual Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of Xist gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Provocation Concentration of Methacholine That Causes a 20% Decrease in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants with Severe Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: intensification of suicidal behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inspiratory esophageal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Diaphragmatic thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Development of pyogenic liver abscess
Endpoint domain: Adverse events/effects
Primary endpoint: Intraocular pressure change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular bio-metrics change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergence of new ovarian follicles with evidence of estradiol production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Short Duration Transient Visual Evoked Potential (SD-tVEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of symptoms of depression or anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Density of vesicular acetylcholine transporter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rates of cardiac death
Endpoint domain: Mortality/survival
Primary endpoint: Acute cellular rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Sulindac concentration in the nevi
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Any formula use at 1 week of age
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Progression of subclinical atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Target Lesion TOTAL Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: toxicity of the combination treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of responders with >20% reduction in pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuous flow maintenance during the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Days of Abstinence (PDA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Monthly Abstinence From Alcohol
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sheehan Disability Scale (SDS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Complete biochemical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Malondialdehyde (MDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AOFAS scale changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Foot Functional Index changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Manchester-Oxford Foot Questionnaire changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of adverse events after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Total number of bleeding days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of self-medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Gross Motor Function Measure 66 Item Set (GMFM-66 IS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first blood transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent surface area involved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: New skin or mucosal blister development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: quality of oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Progesterone plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Endometrial receptivity analysis result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects with treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: increase of body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Myocardial salvage index at 7 d after PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area of myocardial infarction at 7 d after PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of cardiovascular events within 30 d after PCI
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of death, ischemic stroke, TIA, MI, systemic arterial thromboembolism or venous thromboembolism
Endpoint domain: Mortality/survival
Primary endpoint: Any BARC type 3 or 5
Endpoint domain: Adverse events/effects
Primary endpoint: Control of placental bed bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand edema measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a ≥15-Letter Improvement in Best Corrected Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength and endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Childhood Autism Rating Scale (CARS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Gastrointestinal Symptom Severity Scale (GSRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: ASL perfusion MRI data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Control Rates (DCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-related Total Cost Estimates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Microbiological diagnosis of M. tuberculosis infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Alive baby
Endpoint domain: Mortality/survival
Primary endpoint: Annualized Relapse Rate (ARR) at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading to Study Treatment Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of women with gestational diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Re-hospitalization or Death
Endpoint domain: Mortality/survival
Primary endpoint: Investigator Assessment of Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative Protein Algorithmic Score (QPAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Quantitative Protein Algorithmic Score (QPAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of cardiovascular comorbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes of smoking decisional balance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes of self-efficacy of smoking cessation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stride characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Dose-limiting Toxicities (DLTs) in Cycle 1
Endpoint domain: Adverse events/effects
Primary endpoint: Progression-free Survival (PFS) at 6 Months - Expansion Cohort
Endpoint domain: Mortality/survival
Primary endpoint: adherence to Betaseron treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: underlying metabolic risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients with less than a 3-line loss of BCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of inflammatory mediators in aqueous humor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of inflammatory mediators in tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Correlation between tears and aqueous humor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnostic accuracy of SeptiCyte RAPID
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Galectin-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ST2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NGAL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KIM-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: L-FABP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: IL-18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Alpha GST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central Scalp Alopecia Photographic Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Recommended Phase 2 Dose (RP2D) of Atezolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in pepsin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in amylase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Daily inconsolable crying time
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to ingest 100% of total intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to ingest 30% of total intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to perform full oral feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes